Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | ACP1 | P24666 | 1/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11722763 | 0.98 | DRD3 (0.59) | DRD3HRH3ACP1SMARCA2ALDH1A1 | |
| SCHEMBL11713412 | 0.90 | HRH3 (0.56) | DRD3HRH3ACP1 | |
| SCHEMBL3874659 | 0.89 | HRH3 (0.53) | DRD3HRH3ACP1 | |
| Hydrochloric Acid SCHEMBL3876019 | 0.87 | HRH3 (0.52) | DRD3HRH3ACP1 | |
| SCHEMBL3879184 | 0.85 | KAT2B (0.47) | DRD3L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL6528435 | 0.84 | KMT2A (0.51) | ACP1SMARCA2GAAL3MBTL1APAF1 | |
| SCHEMBL29504400 | 0.84 | KMT2A (0.51) | ACP1SMARCA2GAAL3MBTL1APAF1 | |
| Hydrochloric Acid SCHEMBL3882917 | 0.84 | KAT2B (0.46) | DRD3L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL7370267 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL791880 | 0.80 | DRD3 (0.61) | DRD3HRH3ACP1SMARCA2APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2015-05-07 | — | — | US | disclosed |
| US-7022714-B2 | Aryl substituted benzimidazoles and their use as sodium channel blockers | EURO-CELTIQUE S.A. (LU) | 2006-04-04 | — | — | US | disclosed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | disclosed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | disclosed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | DRD3 1284/4885HRH3 104/4885ACP1 4231/4885 |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | DRD3 1260/4885HRH3 104/4885ACP1 4252/4885 |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | CACNA1S, CACNA1I, SCN1A | DRD3 948/4885HRH3 2606/4885ACP1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.